Skip to main content
MENU

3 Day Virtual Event featuring Cutting Edge Presentations from Leading Doctors, Researchers and Experts in the Field of HypoPARAthyroidism

Dr. Bart Clarke

Dr. Bart Clarke

The research program of Bart L. Clarke, M.D., focuses on clinical studies of steroid-induced osteoporosis, transplant-related osteoporosis, age-related osteoporosis, primary hyperparathyroidism, hypoparathyroidism and metabolic bone disease. He has developed collaborative clinical research protocols in these and other areas.

Focus areas
-Steroid-induced osteoporosis. 
-Transplant-associated osteoporosis. 
-Non-hip femoral fractures. .
-Hypoparathyroidism. Phase III and phase I clinical trials of the new drug parathyroid hormone 1-84 in patients with hypoparathyroidism have recently been completed, along with 
a low-dose parathyroid hormone 1-84 clinical trial, with an extension study from the phase III clinical trial still ongoing. Epidemiological studies in Olmsted County of 
comorbidities associated with hypoparathyroidism before and after diagnosis, and the costs of caring for patients with hypoparathyroidism, are ongoing.
-CT colonography to predict bone strength. 
-Other projects in metabolic bone disease. Other projects in metabolic bone disease with fellows in the Mayo Clinic endocrine training program include retrospective chart 
reviews of patients with Erdheim-Chester disease, Hajdu-Cheney syndrome, fibrous dysplasia and primary hyperparathyroidism, and Camurati-Engelmann syndrome.